455 related articles for article (PubMed ID: 17649781)
21. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
[TBL] [Abstract][Full Text] [Related]
23. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
24. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
25. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
[TBL] [Abstract][Full Text] [Related]
26. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
27. [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2003; 42(3):16-9. PubMed ID: 12858485
[TBL] [Abstract][Full Text] [Related]
28. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
29. CA-125 AUC as a new prognostic factor for patients with ovarian cancer.
Mano A; Falcão A; Godinho I; Santos J; Leitão F; Oliveira C; Caramona M
Gynecol Oncol; 2005 May; 97(2):529-34. PubMed ID: 15863156
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
31. [-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-].
Nagele E; Kurz C; Speiser P; Vavra N; Sevelda P
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):79-82. PubMed ID: 8647363
[TBL] [Abstract][Full Text] [Related]
32. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
33. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
34. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
[TBL] [Abstract][Full Text] [Related]
36. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
37. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
[TBL] [Abstract][Full Text] [Related]
38. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery.
Meier W; Stieber P; Hasholzner U; Gropp M; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2945-7. PubMed ID: 9329571
[TBL] [Abstract][Full Text] [Related]
40. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
